Lantheus Holdings is one of the major radiopharmaceutical companies based in Massachusetts, USA, and specializes in radiodiagnostic medical imaging in urology, cardiology and neurology. The company’s flagship product, Pylarify, is a widely used PET imaging agent by urologists to detect prostate cancer in the body, with sales of $989M in 2025. At today’s stock price ($100.55), its market cap stands at $6.59B at a P/E of 24.06.
Per Aug. 3, 2026 Lantheus Press Release of (Merger Announcement), a merger agreement with Curium, a European private pharma company, was announced at a purchase price of $102.50 per share in cash at closing, and up to additional $12.00 per share in Contingent Value Rights (CVRs) over December 31, 2030, an unusual 4.25 year span; the stock price reflects a premium of 38% and 29% to Lantheus’ 60- and 30-day average stock price respectively. The shareholder vote for the proposed merger is scheduled for October 14, 2026.
The Curium proposed and Lantheus agreed valuation is unusually low and goes against the interests of common shareholders; our analysis of this valuation is presented below.
- Forced Cash Distribution with Steep Tax Consequences
Curium will pay cash to Lantheus stockholders and will force the stockholders in taxable accounts (an overwhelming majority) to immediately realize capital gains to incur a massive tax bill that will substantially erode the gains from the extremely low buyout premium: A Massachusetts long-term stockholder (where Lantheus is headquartered) would owe a combined tax of 23.8% on net gains (15% capital gains tax, 3.8% investment gain surtax (NIIT)- a likely scenario for majority stockholder) and 5% State tax). After the tax payment, the realized benefit would be a low 14.2% and 5.2% respectively based on 60 and 30 day average stock price. For higher income stockholders, those that would pay 20% (vs. 15%) long-term capital gains tax, this premium reduces to 9.2% and 0.2%.
The forced increase in earnings for stockholders (e.g. over $50k in gains, a relatively modest amount in our opinion), adds substantially to yearly earnings and disrupts planned tax management activities for such stockholders. The Lantheus Board of Directors have ignored the financial consequences to the common shareholder in this low margin profit transaction.
Few recent acquisition examples are provided below for comparison purposes.
- Valuation Analysis
A commonly used valuation metric EV to Trailing Revenue is used as the comparator, commonly used for businesses with established products. Lantheus, in addition, also had an approval for the generic neuroendocrine tumor radiotherapeutic PNT-2003, that was anticipated to be marketed starting in 2027. This product is anticipated to generate $100M+ revenue- Lutathera (Novartis), the only competitor radiotherapeutic, registered the sales of $816M in 2025.
Valuations of recent radiopharmaceutical acquisitions
| Target Company & Buyer | Deal Value | Target’s Pipeline / Commercial State | Trailing P/E Multiple | Revenue, EV / Trailing Revenue Multiple |
| Lantheus (Curium) | $8.0 Billion | $1.556B TTM revenue, ~ $593M cash reserve. Pipeline: Approved oncology radiotherapeutic PNT-2003 | 24.06 (a) | $1.542B 4.60x-5.03x (b) |
| RayzeBio (BMS) | $4.1 Billion | Pre-revenue; Phase 3 Actinium-225 asset for neuroendocrine tumors. | Negative Earnings | $0 revenue |
| Fusion Pharmaceuticals (Astra Zeneca) | $2.4 Billion | Pre-revenue; Phase 2 alpha-emitting radioconjugates targeting prostate cancer. | Negative Earnings | $0 revenue |
| POINT Biopharma (Eli Lilly) | $1.4 Billion | Early commercial / Pipeline: Phase 3 prostate asset (177Lu-PNT2002) with active supply infrastructure. | Negative Earnings | $36-38M, ~38.4x |
| Advanced Accelerator Applications (Novartis) | $3.9 Billion | Newly approved Lutathera hitting the market. | NM (Negative Earnings) | $126M, ~26x |
a: Yahoo Finance
b: EV/TTM Revenue multiple: @ $102.5/stock= (69.89M x$102.5/1.556B)= 4.60; @ $112/stock: (69.89M x$112/1.556B)= 5.03
In the above table, Lantheus is the only company with commercial products, and has substantial revenue and cash reserves as well as an approved radiotherapeutic with yet to be realized revenue. For other acquisitions in the table, buyers have paid substantially high multiples for companies with no commercial products and anticipated future revenues for pipeline products.
Lantheus would get ~ 4.60-5.03 EV/Revenue multiple for its business, an incredibly low sum for a business with $1.5B yearly sales, ~ $0.6B cash reserves and in our estimate about $0.4B sales potential for the approved radiotherapeutic.
This analysis clearly demonstrates that Lantheus management incredibly shortchanged its shareholders by agreeing to the proposed Curium stock price.
- Major C-suite deficiencies during the deal and cash incentives
Based on the publicly available resources, the posts of Lantheus President and CEO are currently vacant and this multi-billion dollar merger was negotiated during the reign of an interim CEO, a highly unusual occurrence.
According to SEC filings, the interim CEO and Chief Legal Officer would receive substantial transaction bonuses and listed C-suite executives would receive million+ $ cash severance payments (Schedule 14A Proxy Statement, Page 85). It is clear that the C-suite was heavily incentivized for the merger deal while leaving ordinary investors to a meager valuation.
Lantheus certainly did not adhere to its slogan “Find, Fight, Follow” it displays on its website: Lantheus management did not find the right buyer, did not fight for a higher business valuation, did not fight to find the right buyer, did not wait to realize the market potential for a promising radiotherapeutic and did not follow through its promise to stockholders!
This merger does not make sense.
